Anti-c-erbB2-anti-CD3 bifunctional monoclonal antibodiesAlternative Names: Anti-c-erbB-2-anti-CD3-epsilon; Anti-CD3-anti-HER-2 monoclonal antibody; bifunctional antibody
Latest Information Update: 19 Dec 2006
At a glance
- Originator Otsuka Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors; ERBB 2 receptor antagonists; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Apr 1997 No-Development-Reported for Cancer in Japan (Parenteral)